reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In-space manufacturing uses processes such as additive manufacturing (printing a 3D object in successive layers), subtractive manufacturing (making 3D objects by successively removing material from a solid), hybrid manufacturing (usually combining additive manufacturing and subtractive manufacturing) and welding (joining pieces of material by melting or plasticizing along a joint line). In-space manufacturing removes spacecraft design limitations due to launch parameters (mass, vibration, structural load, etc.) and volume limitations imposed by payload size. It allows for recycling of launched materials, utilization space-mined resources and on-demand spare parts production, which enables on-site repair of critical parts (increasing reliability and redundancy) and infrastructure development. It takes advantage of unique space features such as microgravity, ultra-vacuum and containerless processing, which are difficult to do on Earth.
In the age of nationalism, Protestant Germans, whether Conservative (like Otto von Bismarck) or Liberal, accused the Centre of Ultramontanism or having a greater loyalty towards the Pope than to the German nation. After the First Vatican Council, Bismarck launched the Kulturkampf ("cultural struggle") against the Catholic Church. Catholics fought back vigorously and with near-unanimity. The Centre party gained greater support from the Catholic population. Following Bismarck's 1879 turn from free trade to protectionism and from the National Liberal party to the Conservative parties, he also abandoned the unsuccessful Kulturkampf. The Centre party remained a party of opposition to Bismarck, but after his resignation in 1890, it frequently supported the following administrations' policies in the Reichstag, particularly in the field of social security.
== Medical uses == Cilostazol is approved for the treatment of intermittent claudication in the United States and United Kingdom. If no improvement is seen after 3 months, stopping the medication is reasonable. Cilostazol is also used for secondary stroke prevention, though to date no regulatory body has approved it specifically for that indication.
=== Länder in East Germany === In the Soviet occupation zone, five Länder were established which roughly corresponded to the preexisting states and provinces. (The territories east of the Oder–Neisse line had been transferred from the Soviet occupation zone to the Polish authorities as agreed upon at the Potsdam Conference.) The five states were:
== External links == Official website of the Essendon Football Club Official website of the Australian Football League Archived 22 February 2011 at the Wayback Machine 2014 Season scores and results at AFL Tables 2014 Essendon player statistics at AFL Tables
Sources: en.wikipedia.org
=== Diarrhea === Diarrhea is more common and sometimes more severe with flutamide than with other NSAAs. In a comparative trial of combined androgen blockade for prostate cancer, the rate of diarrhea was 26% for flutamide and 12% for bicalutamide. Moreover, 6% of flutamide-treated patients discontinued the medication due to diarrhea, whereas only 0.5% of bicalutamide-treated patients did so. In the case of antiandrogen monotherapy for prostate cancer, the rates of diarrhea are 5 to 20% for flutamide, 2 to 5% for bicalutamide, and 2 to 4% for nilutamide. In contrast to diarrhea, the rates of nausea and vomiting are similar among the three medications.
==== Gamma irradiation ==== Gamma irradiation is produced from the radioisotopes cobalt-60 and caesium-137, which are produced by neutron irradiation of cobalt-59 (the only stable isotope of cobalt) and as a nuclear fission product, respectively. Cobalt-60 is the most common source of gamma rays for food irradiation in commercial scale facilities as it is water-insoluble and hence has little risk of environmental contamination by leakage into the water systems. As for transportation of the radiation source, cobalt-60 is transported in special trucks that prevent release of radiation and meet standards mentioned in the Regulations for Safe Transport of Radioactive Materials of the International Atomic Energy Act. The special trucks must meet high safety standards and pass extensive tests to be approved to ship radiation sources. Conversely, caesium-137 is water-soluble and poses a risk of environmental contamination. Insufficient quantities are available for large-scale commercial use as the vast majority of Caesium-137 produced in nuclear reactors is not extracted from spent nuclear fuel. An incident where water-soluble caesium-137 leaked into the source storage pool requiring NRC intervention has led to near elimination of this radioisotope.
Keratoconus is an eye disorder in which the cornea, the transparent front part of the eye, gradually thins and bulges outward into a cone shape. This causes distorted vision, including blurry vision, double vision, increased nearsightedness, irregular astigmatism, and light sensitivity, which can reduce quality of life. Both eyes are usually affected. The cause is not fully understood but likely involves a combination of genetic, environmental, and hormonal factors. Having a parent, sibling, or child with keratoconus increases risk significantly. Environmental risk factors include frequent eye rubbing and allergies. Diagnosis is typically made with corneal topography, which maps the shape of the cornea and reveals characteristic changes. In early stages, vision is often corrected with glasses or soft contact lenses. As the condition progresses, rigid or scleral contact lenses may be needed. In 2016, the FDA approved corneal collagen cross-linking to halt progression. If vision cannot be improved with contact lenses and the cornea becomes too thin or scarred, a corneal transplant may be necessary. Keratoconus affects about 1 in 2,000 people, though some estimates suggest it may be as common as 1 in 400. It typically develops in late childhood or early adulthood and occurs in all populations, though it may be more common in some ethnic groups, such as people of Asian descent. The name comes from the Greek kéras (cornea) and Latin cōnus (cone).
===== MeSH D08.811.464.257 – carbon-carbon ligases (EC 6.4) ===== MeSH D08.811.464.257.050 – acetyl-coa carboxylase MeSH D08.811.464.257.275 – polyketide synthases MeSH D08.811.464.257.500 – pyruvate carboxylase
== Integrated strategy for functional assignment == The EFI is developing an integrated sequence-structure based strategy for functional assignment by predicting the substrate specificities of unknown members of mechanistically diverse enzyme superfamilies. The approach leverages conserved features within a given superfamily such as known chemistry, identity of active site functional groups, and composition of specificity-determining residues, motifs, or structures to predict function but relies on multidisciplinary expertise to streamline, refine, and test the predictions. The integrated sequence-strategy under development will be generally applicable to deciphering the ligand specificities of any functionally unknown protein.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.